Screener
Indivior Pharmaceuticals, Inc. INDV Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Gross profit | 277 | 221 |
| Operating expenses: | ||
| Selling, general and administrative | 124 | 133 |
| Research and development | 16 | 22 |
| Total operating expenses | 139 | 156 |
| Operating income | 137 | 66 |
| Other (income) and expenses: | ||
| Interest (income) | (3) | (4) |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s business segments — R&D?
- Indivior Pharmaceuticals, Inc. (INDV) reported business segments — R&D of $16M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s business segments — R&D changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s business segments — R&D decreased by 27.3% year-over-year, from $22M to $16M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s business segments — R&D has grown at a 9.4% compound annual growth rate (CAGR), from $74M to $97M.
- What does business segments — R&D mean?
- Represents expenditures dedicated to the discovery, clinical development, and regulatory approval of new pharmaceutical products within the segment. It is a critical indicator of the company's commitment to long-term innovation and future product pipeline viability.
Ask your AI about Indivior Pharmaceuticals, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude